| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT07391657 A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA)… |
Trial sites expanded: 111 -> 116 locations |
| 2026-06-11 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 18 -> 27 locations |
| 2026-06-10 | NCT05623020 A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and… |
Trial sites expanded: 89 -> 111 locations |
| 2026-06-06 | NCT04722146 A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple… |
date change Primary completion moved earlier: 2027-04-07 -> 2025-10-13 |
| 2026-06-06 | NCT04133636 A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed… |
Primary endpoint(s) modified |
| 2026-06-06 | NCT05250973 A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL)… |
date change Primary completion pushed: 2025-05-30 -> 2026-02-04 |
| 2026-06-06 | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… |
Trial sites reduced: 278 -> 271 locations |
| 2026-06-04 | NCT06208150 A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and… |
date change Completion pushed: 2028-03-31 -> 2028-12-31 |
| 2026-06-03 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 12 -> 18 locations |
| 2026-06-03 | NCT03652064 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone… |
Trial completed |
| 2026-06-02 | NCT07601100 Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… |
Primary endpoint(s) modified |
| 2026-06-02 | NCT07601100 Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… |
Trial arms changed: 2 -> 6 |
| 2026-05-16 | NCT07227311 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With… |
Trial sites expanded: 6 -> 10 locations |
| 2026-05-16 | NCT04566328 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple… |
Trial sites expanded: 600 -> 649 locations |
| 2026-05-15 | NCT06152575 MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… |
Trial sites expanded: 131 -> 279 locations |
| 2026-05-15 | NCT05623020 A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and… |
Trial sites expanded: 39 -> 89 locations |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-09 | NCT07635511 Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies | Phase 3 | Not Yet Recruiting |
| 2026-06-09 | NCT07637526 Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed… | Not Yet Recruiting | |
| 2026-06-03 | NCT07624513 Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction… | Phase 3 | Not Yet Recruiting |
| 2026-05-29 | NCT07614360 Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib… | Phase 2 | Not Yet Recruiting |
| 2026-05-27 | NCT07609706 A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd)… | Phase 1 | Not Yet Recruiting |
| 2026-05-22 | NCT07601100 Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant… | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07297329 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib… | Multiple Myeloma (MM) | Recruiting |
| NCT07388602 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib… | Amyloidosis | Recruiting |
| NCT06022939 | Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone… | AL Amyloidosis | Recruiting |
| NCT06413498 | A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants… | Multiple Myeloma | Recruiting |
| NCT04566328 | Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple… | Plasma Cell Myeloma | Recruiting |
| NCT06918002 | Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of… | Multiple Myeloma, Newly Diagnosed | Recruiting |
| NCT07222761 | A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination… | Relapsed and/or Refractory Multiple Myeloma (RRMM) | Recruiting |
| NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People… | Multiple Myeloma | Recruiting |
| NCT06208150 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and… | Multiple Myeloma | Recruiting |
| NCT05623020 | A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and… | Multiple Myeloma | Recruiting |
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard… | Multiple Myeloma | Recruiting |
| NCT05519085 | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus… | Relapsed or Refractory Multiple Myeloma | Recruiting |
| NCT05561387 | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a… | Plasma Cell Myeloma | Recruiting |
| NCT07391657 | A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA)… | Relapsed Refractory Multiple Myeloma | Recruiting |
| NCT01208662 | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With… | Multiple Myeloma | Active, Not Recruiting |
| NCT03617731 | Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd)… | Multiple Myeloma | Active, Not Recruiting |
| NCT00572169 | UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy | Multiple Myeloma | Active, Not Recruiting |
| NCT03710603 | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE… | Multiple Myeloma | Active, Not Recruiting |
| NCT04751877 | Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone… | Multiple Myeloma | Active, Not Recruiting |
| NCT03729804 | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and… | Multiple Myeloma | Active, Not Recruiting |
| NCT05257083 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by… | Multiple Myeloma | Active, Not Recruiting |
| NCT04975997 | Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus… | Multiple Myeloma | Active, Not Recruiting |
| NCT05572515 | A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone… | Relapsed or Refractory Multiple Myeloma | Active, Not Recruiting |
| NCT04246047 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone… | Multiple Myeloma | Active, Not Recruiting |
| NCT06868654 | China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin… | Multiple Myeloma | Active, Not Recruiting |